MBRX ▲ +4.2% - Moleculin Biotech, Inc. $MBRX - Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings Moleculin Biotech rose 4.2% today following an announcement that the company will present new data on its Annamycin treatment candidate at the American Association for Cancer Research conference focused on pancreatic cancer, as well as at two European scientific meetings. The upcoming presentations of clinical or research data typically signal progress in the company's pipeline and can attract investor interest in its development efforts. 14-SEP-2026 08:35 AM ET